Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (NY:CANF)

0.2550 +0.0050 (+2.00%)
Streaming Delayed Price Updated: 1:21 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd Sponsored ADR (Israel)

< Previous 1 2 3 4 5 6 7 Next >
News headline image
45 Biggest Movers From Yesterday ↗
Gainers Puxin Limited (NYSE: NEW) shares surged 80% to close at $0.54 on Wednesday after reporting results for the second quarter. United Time Technology Co., Ltd. (NASDAQ: UTME... 
Via Benzinga
News headline image
26 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Puxin Limited (NYSE: NEW) jumped 100.5% to $0.6016 after reporting results for the second quarter. ShiftPixy, Inc. (NASDAQ: PIXY) climbed 38.4% to $1.55 after surging 43... 
Via Benzinga
News headline image
CANF Stock: The Cancer-Fighting News Sending Can-Fite Higher Today ↗
Can-Fite BioPharma is rising on Wednesday following positive Phase 2 data on its liver cancer treatment. Can it help turn CANF stock around? 
Via InvestorPlace
News headline image
Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
38 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) climbed 71.4% to $13.06 after gaining... 
Via Benzinga
News headline image
55 Biggest Movers From Yesterday ↗
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Good morning, trader! We're kicking off the day with a dive into some of the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
News headline image
26 Stocks Moving in Tuesday's Pre-Market Session ↗
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) rose 102% to $5.13 in pre-market trading after the company reported pan-coronavirus monoclonal antibody cocktail that retains... 
Via Benzinga
News headline image
65 Biggest Movers From Yesterday ↗
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Dow Tumbles 500 Points; Bluerock Residential Growth Shares Spike Higher ↗
Toward the end of trading Monday, the Dow traded down 1.42% to 34,862.49 while the NASDAQ fell 1.38% to 14,960.51. The S&P also fell, dropping 1.34% to 4,558.87. The U.S. has... 
Via Benzinga
News headline image
Can-Fite Shares Rally As Namodenoson Clears All Cancer Lesions In Liver Cancer Patient ↗
Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last liver cancer patient treated under an Open-Label Extension program of its concluded Phase 2 study of Namodenoson... 
Via Benzinga
News headline image
Mid-Day Market Update: Crude Oil Drops Over 5%; Society Pass Shares Jump ↗
Midway through trading Monday, the Dow traded down 1.78% to 34,735.33 while the NASDAQ fell 1.43% to 14,952.69. The S&P also fell, dropping 1.59% to 4,547.26. The U.S. has the... 
Via Benzinga
News headline image
RKT Stock: 15 Things to Know as Rocket Moves Beyond Mortgages With Truebill Deal ↗
Rocket Companies (RKT) stock is on the move Monday following news of a $1.275 billion acquisition deal with Truebill. 
Via InvestorPlace
News headline image
CANF Stock Alert: The Liver Cancer News Catapulting Can-Fite BioPharma Shares Higher Today ↗
Can-Fite BioPharma (CANF) stock is rocketing higher on Monday thanks to new data from a Phase II clinical trial for liver cancer. 
Via InvestorPlace
News headline image
38 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell 2000 Index. Can-Fite BioPharma Ltd. (NYSE: CANF... 
Via Benzinga
News headline image
Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Piclidenoson Takes On Otezla, a $13 Billion Psoriasis Drug ↗
Photo by Hal Gatewood on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
News headline image
Can-Fite Expects Data Readout From Late-Stage Psoriasis Study With Piclidenoson In Q1 2022 ↗
Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last of approximately 400 psoriasis patients enrolled in its Phase 3 Comfort study is scheduled to complete a 16-week... 
Via Benzinga
News headline image
Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Cannabis-Focused Biotech Company Can-Fite Reports Q3 Financial Results & Clinical Updates ↗
Cannabis-focused biotech company Can-Fite BioPharma Ltd. (AMEX:C... 
Via Benzinga
News headline image
Earnings Scheduled For November 26, 2021 ↗
Companies Reporting Before The Bell Pinduoduo Inc. (NASDAQ:PDD) is expected to report quarterly earnings at $0.02 per share on revenue of $4.16 billion. BlueCity Holdings Limited... 
Via Benzinga
News headline image
Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite's Kickstarts Piclidenoson Study For Canine Osteoarthritis ↗
Can-Fite BioPharma Ltd (NYSE: CANF) has commenced a safety and efficacy study of Piclidenoson to treat osteoarthritis in dogs. Safety results are expected in... 
Via Benzinga
News headline image
Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite’s Findings on Cannabis Compound’s Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD’s The Liver Meeting® 2021 Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite’s NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite CEO to Present Namodenoson’s Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal ↗
PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule... 
Via Benzinga
News headline image
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
From Can-Fite BioPharma Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.